GEO DataSets

Temporal analysis of peripheral blood from 18 relapsed CLL patients treated with a maximum of 6 doses (0.2-6mg/kg) of SPC2996, an antisense molecule targeting the mRNA of Bcl-2 oncoprotein. Results provide insight into the molecular basis of the immunostimulatory effects of SPC2996 in CLL.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 6 dose, 18 individual, 4 time sets

Platform:

GPL570

Series:

GSE27858

56 Samples

Download data: CEL, CHP

(Submitter supplied) SPC2996 is a novel locked nucleic acid (LNA) phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We investigated the mechanism of action of SPC2996 and the basis for its clinically observed immunostimulatory effects in chronic lymphocytic leukemia (CLL). Patients with relapsed CLL were treated with a maximum of six doses of SPC2996 (0.2-6mg/ kg) in a multicenter phase I trial. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4284

Platform:

GPL570

56 Samples

Download data: CEL, CHP

(Submitter supplied) Thalidomide Exerts Distinct Molecular Antileukemic Effects and Combined Thalidomide/Fludarabine Therapy is Clinically Effective in High-Risk Chronic Lymphocytic Leukemia Background: Thalidomide represents a promising immunomodulatory drug that targets both leukemia cells and the tumor microenvironment. Methods: We treated chronic lymphocytic leukemia (CLL) patients with a combined thalidomide/fludarabine regimen and monitored cellular and molecular changes induced by thalidomide in-vivo prior to fludarabine treatment. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

40 Samples

Download data: CEL, CHP

(Submitter supplied) Objective. B-cell chronic lymphocytic leukemia is a heterogeneous disease with a pronounced variation in the clinical course. With the purpose of identifying genes that could be related to disease progression, we have performed gene expression profiling on B-CLL patients with an indolent disease and patients with a progressive disease with need for therapy. Materials and Methods. We applied the Affymetrix GeneChip technique to 11 B-CLL patients with stable and 10 patients with clinically progressive disease. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS1388

Platform:

GPL8300

21 Samples

Download data

Analysis of primary lymphocytes from B-cell chronic lymphocytic leukemia (B-CLL) patients. Lymphocytes from patients with indolent B-CLL compared to those with progressive B-CLL. Results identify putative gene markers of B-CLL progression from a stable to an aggressive state.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 disease state sets

Platform:

GPL8300

Series:

GSE2403

21 Samples

Download data

(Submitter supplied) Purpose: Accurate prediction of clinical response is the prerequisite for individualized therapy in chronic lymphocytic leukemia (CLL). We hypothesized that sequential assessment of gene expression changes early during therapy may well reflect behaviour of the leukemic clone in response to specific drugs. Patients and Methods: Gene expression profiles (GEP) were determined in CD19+ selected B-cells from 20 patients treated with fludarabine and cyclophosphamide (FC) (N=10) or FC plus rituximab (FCR) (N=10). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS3829

Platform:

GPL570

50 Samples

Download data: CEL

Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 5 agent sets

Platform:

GPL570

Series:

GSE15490

50 Samples

Download data: CEL

(Submitter supplied) Chronic lymphocytic leukemia (CLL) is a common and heterogeneous disease. An accurate prediction of outcome is highly relevant for the development of personalized treatment strategies. Microarray technology was shown to be a useful tool for the development of prognostic gene expression scores. However, there are no gene expression scores which are able to predict overall survival in CLL based on the expression of few genes that are better than established prognostic markers. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL570 GPL96 GPL97

195 Samples

Download data: CEL